Severe keratitis in adults w/ dry eye disease which has not improved despite treatment w/ tear substitutes. Severe vernal keratoconjunctivitis (VKC) in adolescent & childn ≥4 yr.
Administer at least 15 min apart if >1 topical ophth medicinal product is being used. Severe keratitis in dry eye diseaseAdult Max: 1 drop once daily to affected eye(s) at bedtime. Reassess treatment response at least every 6 mth. Severe VKCAdolescent & childn ≥4 yr 1 drop qid (morning, noon, afternoon & evening) to each affected eye. Maintain dose if signs & symptoms persist after end of season or decrease to 1 drop bid once control is achieved. Max: 1 drop for each instillation in affected eye(s).
Not recommended to use w/ contact lenses. Patients w/ glaucoma; active orofacial herpes simplex infection, history of ocular herpes, varicella-zoster, or vaccinia virus infection. May affect host defences against local infections & malignancies. May cause eye irritation due to cetalkonium Cl. Monitor patients w/ severe keratitis. Remove contact lenses before instillation of eye drops at bedtime & may be reinserted at wake-up time. Perform regular eye exam every 3-6 mth when used for >12 mth. Concomitant use w/ β-blockers & corticosteroids. May affect ability to drive & use machines. Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation. Childn & adolescents <18 yr w/ severe keratitis; childn <4 yr & adults >18 yr w/ severe VKC.
Sign Out
